Treats inflammatory lesions of rosacea. ANDA 216692, held by Cosette Pharmaceuticals. Metronidazole.
As of Nov 21, 2026, ANDA 216692 (Metronidazole), held by Cosette Pharmaceuticals, was first approved by FDA on Jan 23, 2023, with 0 approved supplements and 0 published complete response letters.
Metronidazole gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 23, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metronidazole1% · gel;topical | Metronidazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters